A Novel Therapeutic Approach in the Treatment of Pulmonary Arterial Hypertension: Allium ursinum Liophylisate Alleviates Symptoms Comparably to Sildenafil

被引:11
|
作者
Bombicz, Mariann [1 ]
Priksz, Daniel [1 ]
Varga, Balazs [1 ]
Kurucz, Andrea [1 ]
Kertesz, Attila [2 ]
Takacs, Akos [1 ]
Posa, Aniko [3 ]
Kiss, Rita [1 ]
Szilvassy, Zoltan [1 ]
Juhasz, Bela [1 ]
机构
[1] Univ Debrecen, Dept Pharmacol & Pharmacotherapy, Fac Med, H-4032 Debrecen, Hungary
[2] Univ Debrecen, Dept Cardiol, Fac Med, H-4032 Debrecen, Hungary
[3] Univ Szeged, Fac Sci & Informat, Dept Physiol Anat & Neurosci, H-6726 Szeged, Hungary
关键词
Allium ursinum; pulmonary arterial hypertension; phosphodiesterase; sildenafil; monocrotaline; CGMP PHOSPHODIESTERASE; MODEL; INHIBITION; RATS; METABOLISM; EXPRESSION; BIOMARKERS; MORTALITY; PRESSURE; ISCHEMIA;
D O I
10.3390/ijms18071436
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Right-sided heart failure-often caused by elevated pulmonary arterial pressure-is a chronic and progressive condition with particularly high mortality rates. Recent studies and our current findings suggest that components of Wild garlic (Allium ursinum, AU) may play a role in reducing blood pressure, inhibiting angiotensin-converting enzyme (ACE), as well as improving right ventricle function in rabbit models with heart failure. We hypothesize that AU may mitigate cardiovascular damage caused by pulmonary arterial hypertension (PAH) and has value in the supplementary treatment of the complications of the disease. In this present investigation, PAH was induced by a single dose of monocrotaline (MCT) injection in Sprague-Dawley rats, and animals were divided into 4 treatment groups as follows: I. healthy control animals (Control group); II. pulmonary hypertensive rats (PAH group); III. pulmonary hypertensive rats + daily sildenafil treatment (Sildenafil group); and IV. pulmonary hypertensive rats + Wild garlic liophylisate-enriched chow (WGLL group), for 8 weeks. Echocardiographic measurements were obtained on the 0 and 8 weeks with fundamental and Doppler imaging. Isolated working heart method was used to determinate cardiac functions ex vivo after thoracotomy on the 8th week. Histological analyses were carried out on excised lung samples, and Western blot technique was used to determine Phosphodiesterase type 5 enzyme (PDE5) expression in both myocardial and pulmonary tissues. Our data demonstrate that right ventricle function measured by echocardiography was deteriorated in PAH animals compared to controls, which was counteracted by AU treatment. Isolated working heart measurements showed elevated aortic flow in WGLL group compared to PAH animals. Histological analysis revealed dramatic increase in medial wall thickness of pulmonary arteries harvested from PAH animals, but arteries of animals in sildenafil-and WGLL-treated groups showed physiological status. Our results suggest that bioactive compounds in Allium ursinum could have beneficial effects in pulmonary hypertension.
引用
收藏
页数:19
相关论文
共 50 条
  • [1] Sildenafil citrate for the treatment of pulmonary arterial hypertension
    Antoniu, SA
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (06) : 825 - 828
  • [2] Sildenafil in the treatment of pulmonary arterial hypertension in scleroderma
    Gokhale, S.
    Kumar, U.
    Handa, R.
    Yadav, R.
    Srinivas, V.
    Kumar, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 209 - 209
  • [3] A Review of Sildenafil in the Treatment of Pediatric Pulmonary Arterial Hypertension
    Krishnan, Usha
    Lovig, Leif
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1329 - 1333
  • [4] Sildenafil - a new method for treatment of pulmonary arterial hypertension
    Pierre, Jacques
    PRESSE MEDICALE, 2006, 35 (09): : 1275 - 1275
  • [5] An update on sildenafil in the treatment of pulmonary arterial hypertension in the neonate
    Schellack, Natalie
    Thom, Lorraine
    van Blerk, Zanli
    SA PHARMACEUTICAL JOURNAL, 2015, 82 (07) : 22 - 25
  • [6] Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH)
    Rashid, Jahidur
    Patel, Brijeshkumar
    Nozik-Grayck, Eva
    McMurtry, Ivan F.
    Stenmark, Kurt R.
    Ahsan, Fakhrul
    JOURNAL OF CONTROLLED RELEASE, 2017, 250 : 96 - 106
  • [7] Comparison of preventive effect of sildenafil and therapeutic effect of sildenafil treatment in rats with monocrotaline-induced pulmonary arterial hypertension
    Yoshiyuki, Rieko
    Fukushima, Ryuji
    Tanaka, Ryo
    Machida, Noboru
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2016, 78 (10): : 1607 - 1610
  • [8] Novel sildenafil nanoformulation as a potential therapy for pulmonary arterial hypertension
    Mohamed, Nura
    Abou Saleh, Haissam
    Kameno, Yu
    Marei, Isra
    de Nucci, Gilberto
    Ahmetaj-Shala, Blerina
    BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (11) : 2508 - 2509
  • [9] The addition of sildenafil to bosentan therapy in the treatment of pulmonary arterial hypertension
    Mathai, SC
    Fisher, MR
    Housten-Harris, T
    Girgis, RE
    Hassoun, PM
    CHEST, 2005, 128 (04) : 161S - 162S
  • [10] Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia
    Lilyasari, Oktavia
    Subekti, Yusuf
    Atika, Nur
    Dinarti, Lucia Kris
    Putri, Septiara
    Opitasari, Cicih
    Anggraini, Anggita Bunga
    Bussabawalai, Thanaporn
    Teerawattananon, Yot
    BMC HEALTH SERVICES RESEARCH, 2019, 19 (01)